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Background-—Up to half of patients undergoing percutaneous coronary intervention have multivessel coronary artery disease
(MVD) with conflicting data regarding optimal revascularization strategy in such patients. This paper assesses the evidence for
complete revascularization (CR) versus incomplete revascularization in patients undergoing percutaneous coronary intervention,
and its prognostic impact using meta-analysis.
Methods and Results-—A search of PubMed, EMBASE, MEDLINE, Current Contents Connect, Google Scholar, Cochrane library,
Science Direct, and Web of Science was conducted to identify the association of CR in patients with multivessel coronary artery
disease undergoing percutaneous coronary intervention with major adverse cardiac events and mortality. Random-effects meta-
analysis was used to estimate the odds of adverse outcomes. Meta-regression analysis was conducted to assess the relationship
with continuous variables and outcomes. Thirty-eight publications that included 156 240 patients were identified. Odds of death
(OR 0.69, 95% CI 0.61-0.78), repeat revascularization (OR 0.60, 95% CI 0.45-0.80), myocardial infarction (OR 0.64, 95% CI 0.50-
0.81), and major adverse cardiac events (OR 0.63, 95% CI 0.50-0.79) were significantly lower in the patients who underwent CR.
These outcomes were unchanged on subgroup analysis regardless of the definition of CR. Similar findings were recorded when CR
was studied in the chronic total occlusion (CTO) subgroup (OR 0.65, 95% CI 0.53-0.80). A meta-regression analysis revealed a
negative relationship between the OR for mortality and the percentage of CR.
Conclusion-—CR is associated with reduced risk of mortality and major adverse cardiac events, irrespective of whether an
anatomical or a score-based definition of incomplete revascularization is used, and this magnitude of risk relates to degree of CR.
These results have important implications for the interventional management of patients with multivessel coronary artery disease.
( J Am Heart Assoc. 2016;5:e004598 doi: 10.1161/JAHA.116.004598)
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P ercutaneous coronary intervention (PCI) is the mostcommon form of coronary revascularization in patients
with stable coronary artery disease and acute coronary
syndromes (ACS).1 Multivessel coronary artery disease is
common and affects more than half of patients who have an
ACS.2,3 In these patients there is a lack of evidence on whether
revascularization that is restricted to the culprit artery is
sufficient or whether multivessel PCI would lead to an improved
prognosis. Angiographically incomplete revascularization (IR)
has been considered to be a poor prognostic feature in multiple
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observational studies and post hoc analyses of randomized
controlled trials.4-8 The only prospective randomized controlled
trial (RCT) outside the context of ST-elevation myocardial
infarction (STEMI) comparing the safety, efficacy, and costs of
complete versus “culprit” vessel revascularization in multives-
sel coronary artery disease treated with PCI showed no
difference in major adverse cardiovascular event (MACE) rates
between the 2 strategies, with a lower cost associated with the
culprit-only strategy in the shorter term, although costs
equalized in the longer term.9
Recent data from randomized trials including the PRAMI,10
CvLPRIT,11 and DANAMI-3-PRIMULTI trials,12 which recruited
patients presenting with STEMI undergoing primary PCI, have
shown that multivessel “complete” revascularization is asso-
ciated with better outcomes than culprit-only revasculariza-
tion. However, despite these data, important uncertainties still
exist about the optimal strategy for such patients. Further-
more, in patients with stable coronary artery disease,
international PCI guidelines do not provide guidance about
the performance of complete revascularization (CR) versus IR,
although functional assessment of lesions using noninvasive
tests or fractional flow reserve (FFR) is recommended to avoid
unnecessary treatment of nonsignificant stenosis13-15
because this is associated with adverse outcomes.
In a previous meta-analysis by Garcia et al16 including
~90 000 individuals with multivessel disease, incomplete
revascularization in 25 938 CABG patients (29% from 16
studies) and 63 945 PCI patients (71% from 24 publications)
was associated with increased risk of mortality, myocardial
infarction, and repeat revascularization irrespective of the
revascularization strategy employed. Since then many studies
have been published including large registry data,13,17 post
hoc analyses of randomized trials,6,18,19 and observational
studies7,20-24 to assess effectiveness of complete coronary
revascularization.
Our objectives were to assess and update the current
evidence for complete revascularization and its prognostic
impact in PCI by performing a meta-analysis of 38 studies
including over 150 000 patients (excluding the STEMI and
surgical revascularization cohorts).
Methods
Eligibility Criteria
The Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) guidelines were followed.25 Studies
were selected of patients who underwent PCI, reporting
mortality or cardiovascular events among patients with and
without complete revascularization with no restriction based
on study design or the indication for PCI. Publications that did
not report either mortality or MACE were excluded.
Search Strategy
A search was done of PubMed, EMBASE, MEDLINE, Current
Contents Connect, Google Scholar, Cochrane library, Science
Direct, and Web of Science to October 2016. We used the
following search terms: “Complete revascularization” OR
“Incomplete revascularization” AND “Percutaneous coronary
intervention” OR “PCI.” These keywords were searched as
text words as well as exploded medical subject headings
when feasible. The search strategy example for MEDLINE is as
follows: 1 Complete revascularization.mp. (913), 2 Incomplete
revascularization.mp. (358), 3 1 or 2 (1125), 4 exp *Percu-
taneous Coronary Intervention/(31 192), 5 3 and 4 (292). We
excluded the STEMI and surgical revascularization cohorts.
The definitions of “complete revascularization” are given in
Table 1. Studies in all languages were included. The bibli-
ographies of the included studies and relevant review articles
were checked for additional relevant articles.
Study Selection and Data Extraction
Two reviewers (V.N. and M.M.) independently checked all
titles and abstracts for studies potentially meeting the
inclusion criteria. The full reports of these studies were
retrieved, and data were independently extracted on study
design, participant characteristics, complete revascularization
definition, outcome events, and follow-up.
Quality Assessment
The Newcastle-Ottawa Scale (NOS)26 was used as an
assessment tool for selection, comparability, and outcome
assessment. Study quality was rated on a scale from 1 (very
Table 1. Definitions of Complete Revascularization
Anatomical
or traditional
All diseased arterial systems with vessel
size 1.5 (2.0-2.25 mm for PCI) with at least
1 significant stenosis >50% receive a stent
Functional All ischemic myocardial territories are
grafted (or stented); areas of old infarction
with no viable myocardium are not
required to be reperfused
Numerical Number of distal anastomoses number of
diseased coronary segments/systems
Score-based Scoring of stenosis in different vessels.
Different weight given to different vessels
according to number of myocardial
segments supplied. A residual score of
0 is usually considered equivalent to CR
Physiology-based All coronary lesions with FFR less than
or equal to 0.75 to 0.80 receive a stent
CR indicates complete revascularization; FFR, fractional flow reserve; PCI percutaneous
coronary intervention.
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poor) to 9 (high). Publication bias was assessed using an
Egger regression model27 and the fail-safe number method.28
Data Analysis
The program Comprehensive Meta-analysis (version 2.0) was
used to conduct DerSimonian and Laird random-effects meta-
analysis.29 Risk ratio (RR) and 95% confidence intervals (CI)
were calculated. Adjusted or propensity-matched risk
estimates were used when available. Meta-regression analysis
was conducted to assess the relationship with continuous
variables and outcomes. The Cochrane Q-statistic (I2) was
used to assess the consistency among studies, with I2<25%
considered low, I2>50% moderate, and I2>75% high
heterogeneity.30
Results
Study Population
A total of 425 publications were screened; then, 38 relevant
studies* including 156 240 patients met our selection
criteria (Figure 1). We excluded previous meta-analysis16,54-66
and trials comparing target lesion revascularization versus
upfront revascularization STEMI.10-12,67-70 The studies
included were mostly observational and included large
registries13,17,50,53 or post hoc analyses of randomized trials
such as the SYNTAX trial,6 FAME trial,18 ARTS trial,31 ARTS-II
Study,44 MASS II trial,36 BARI trial, 33 CABRI trial,34 and the
ACUITY trial.8 Only 1 randomized single-center trial9 has been
published so far that compares the outcomes of complete and
incomplete percutaneous revascularization.
The publication dates ranged from 1988 to 2016, and the
follow-up period for patients ranged between 1 and 11 years.
The numbers of patients in each study were variable and
ranged between 192 and 23 342 individuals. Most of these
participants were male, and the percentage of females ranged
from 7% to 37%; the mean age reported in the studies varied
from 52 to 68 years. The percentage of ACS ranged from 0%
to 100%.
Most of the studies used an anatomic definition for
complete revascularization. Only 1 study used a functional
definition (coronary lesions with fractional flow reserve ≤0.75
to 0.80 received a stent),43 and 7 others utilized a score-
based assessment (SYNTAX score; a residual score of 0 is
considered to be complete revascularization) for complete
revascularization.5,6,17,19,21-23 The percentage of complete
revascularization ranged from 17% to 70% with a mean of
42.7%. The study characteristics have been tabulated in
Table 2. The results of the studies that evaluated incomplete
revascularization and adverse outcomes are shown in Table 3.
Outcomes: Overall and Subgroup Analysis Based
on CR Definition and Chronic Total Occlusion
Revascularization
There was a significantly lower risk of death with complete
revascularization (Figure 2, OR 0.69, 95% CI 0.61-0.78)
among 36 studies† that reported this outcome. This lower
risk of mortality was maintained after performing subgroup
analysis based on the anatomic definition of complete
revascularization‡ (OR 0.69, 95% CI 0.61-0.79), although this
did not reach statistical significance for score-based defini-
tions6,8,18,19,24,39,44,46 (OR 0.73, 95% CI 0.50-1.07). Similar
findings were recorded in the complete chronic total occlu-
sion (CTO)-revascularization cohort (5 studies,4,38,48,50,52 OR
0.65, 95% CI 0.53-0.80) and in the non-CTO cohort (OR 0.71,
95% CI 0.61-0.82).§
The outcome of repeat revascularization was reported in 17
studies,k and there was statistically significantly lower rate in
complete revascularization populations (Figure 3, OR0.60, 95%
CI 0.45-0.80). After subgroup analysis with respect to definition
of complete revascularization, this benefit was maintained in
studies that used anatomic¶ (OR 0.58, 95% CI 0.41-0.82) and
score-based definitions6,8,18,19 (OR 0.64, 95% CI 0.54-0.76).
Myocardial infarction was reported in 17 studies,# and a
statistically significantly lower rate was observed (Figure 4,
OR 0.63, 95% CI 0.50-0.79). This finding was maintained with
respect to anatomic** (OR 0.60, 95% CI 0.45-0.81) and
score-based definitions6,8,18,19 (OR 0.64, 95% CI 0.51-0.79) of
complete revascularization.
MACE was reported in 14 studies,†† and a significantly
lower rate was observed (Figure 5, OR 0.66, 95% CI 0.51-
0.85). This finding was maintained with respect to ana-
tomic7,9,13,17,20,35,47,56 (OR 0.64, 95% CI 0.46-0.89) and
score-based definitions6,8,18,19,39 (OR 0.68, 95% CI 0.50-
0.93) of complete revascularization.
Stent thrombosis was reported in only 3 studies,6,17,19,44
and there was no impact of complete revascularization in its
incidence (Figure 6, OR 0.81, 95% CI 0.49-1.33).
In a subgroup analysis of 2 studies8,71 that reported on
outcomes in patients who exclusively had acute coronary
syndromes (ACS), no significant benefit was observed
*References 4-9, 13, 17, 18, 20-24, 31-53, 71.
†References 4-9, 13, 17, 18, 20-24, 31-50, 52, 53.
‡References 4, 7, 9, 13, 17, 20-24, 31-38, 40-43, 45, 47-50, 52, 53.
§References 5-9, 13, 17, 18, 20-24, 31-37, 39-47, 49, 53.
kReferences 6, 8, 9, 13, 17-20, 31, 33, 37, 41, 49, 53, 71.
¶References 9, 13, 17, 20, 31, 33, 37, 41, 49, 53, 71.
#References 6, 8, 9, 13, 17-20, 31, 33, 37, 41, 49, 53, 71.
**References 9, 13, 17, 20, 31, 33, 37, 41, 49, 53, 71.
††References 6-9, 13, 17-20, 35, 39, 47, 53, 56.
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(OR 0.71, 95% CI 0.44-1.11) in mortality or MACE (OR 0.79,
95% CI 0.54-1.17).
Regression Analysis Based on Proportion of CR
A regression analysis was conducted, and a negative
relationship was observed between the mortality and the
percentage of CR. From the regression model, there was very
strong evidence that the OR of mortality was inversely related
to CR with a P<0.001 (df=34). Log OR of mortality decreased
by 1.25 (95% CI 1.64 to 0.88) for every 1% increase in CR.
There was no relationship between the odds ratio of mortality
and year of publication.
Heterogeneity and Publication Bias
There was significant heterogeneity noted among the different
studies that could be explained by diverse population groups.
The degree of heterogeneity reduced to a minimal amount
once subgroup analysis was performed based on a score-
based definition of complete revascularization, suggesting
similar study designs and population cohorts. The results have
been summarized in Table 4. There was no publication bias
identified using the Egger regression model.
Discussion
In our meta-analysis of 38 studies including over 156 240
patients undergoing PCI, we observed that fewer than half of all
patients with multivessel coronary artery disease have CR. We
observed that CR is associated with a lower rate of mortality,
myocardial infarction, and MACE, irrespective of whether an
anatomical or a score-based definition of IR was used, and that
the magnitude of risk relates to degree of CR on meta-
regression. Our analysis builds on the work done by Garcia
et al16 by placing a focus on PCI and including new studies.
Figure 1. Flow diagram of included studies. STEMI indicates ST-elevation myocardial infarction.
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Table 3. Results of Studies That Evaluated Incomplete Revascularization and Adverse Outcomes
Study Results
Appleby et al32 Better survival with CR (871% vs 781%, P<0.001).
Residual disease significant independent predictor of the need for repeat procedures
Bourassa et al33 CR (n 579) (%) IR (n 317) (%) P Value
Death 87.5 84.0 0.13
MI 83.8 84.1 0.91
Repeat revascularization 46.3 42.8 0.48
Angina 79.8 75.6 0.22
Breeman et al34 At 1 month
PTCA Remaining lesions 0 1 2 ≥3
Death (%) 2.1 0.7 0.8 2.5
MI (%) 4.9 2.8 3.3 5.0
(Repeat revascularization) CABG (%) 2.8 1.4 7.4 20.2
(Repeat revascularization) PTCA (%) 4.2 3.5 5.7 5.9
At 1 year
PTCA Remaining lesions 0 1 2 ≥3
Death (%) 5.4 2.0 3.3 5.0
MI (%) 5.4 3.4 4.9 6.7
(Repeat revascularization) CABG (%) 7.4 9.5 18.0 37.0
(Repeat revascularization) PTCA (%) 25.0 22.5 23.8 19.3
Capodanno et al21 Cardiac mortality at 2 years: 3.3%, 4.5%, and 19.8% in the CR
Chung et al35 Propensity score-matched (n=550)
Adjusted HR [95% CI]
Death 0.66 [0.34-1.28]
Death and MI 0.51 [0.28-0.95]
Death, MI, and repeat revascularization 0.84 [0.60-1.19]
Cardiac death 0.50 [0.18-1.40]
Cardiac death and MI 0.39 [0.16-0.96]
Any adverse cardiac events 0.93 [0.64-1.35]
D’Oliveira Vieira et al36 A statistically significant difference was observed for the PCI group (CR, 6 individuals died, IR 20 individuals died)
Deligonul et al37 Outcomes Events/CR Total Events/IR Total
Repeat revascularization CABG/PTCA 24/118, 73/255
MI 3/118, 9/255
Death 6/118, 14/255
Gao et al7 At 36 months, cardiac death was significantly greater in the IR cohort (2.55% vs 1.13%, log-rank test: P=0.016),
but there was no difference in the 3-year rates of MI, TVR, and MACE between the 2 cohorts. Angiographic
IR had a greater risk of cardiac death (adjusted hazard ratio [HR] 2.56, 95% confidence interval [CI] 1.03-6.41)
Genereux et al6 At 60 months, rates of MACE were linked with IR
Hambraeus et al13 Unadjusted HR (IR compared with CR): repeat revascularization 2.05 (95% CI 1.80-2.32; P<0.0001); combined
endpoint of death/MI, HR was 1.92 (95% CI 1.77-2.09; P<0.0001) for IR compared with CR
Hannan et al4 Adjusted HR for IR patients compared to CR patients for death was 1.15 (95% CI 1.01-1.30). Repeat revascularization:
10.09% for CR patients and 11.46% for IR patients (P=0.16)
Hannan et al38 (IR vs CR) 18-month mortality (adjusted HR 1.23, 95% CI 1.04-1.45) and 18-month MI/mortality (adjusted HR 1.27,
95% CI 1.09-1.47). The adjusted survival rates for CR and IR were 94.9% and 93.8% (P=0.01), and the
freedom-from-MI rates were 93.3% and 91.7% (P=0.002)
Ijsselmuiden et al9 (IR vs CR) MACE rates at 1 month (14.4% vs 9.3%), 1 year (32.4% vs 26.9%), and 4.61.2 years (40.4% vs 34.6%)
were similar in both cohorts
Kobayashi et al18 Patients with MACE had comparable RSS and SRI after PCI: RSS 6.0 [IQR 3.0-10.0] vs 5.0 [IQR 2.0-9.5], P=0.51;
SRI 60.0% [IQR 40.9%-78.9%] vs 58.8% [IQR 26.7%-81.8%], P=0.24, respectively. Kaplan-Meier analysis showed
comparable 12-month rate of MACE with different RSS/SRI (log-rank P=0.55 and 0.54, respectively)
Kim et al39 (CR vs IR) MACE HR 0.82 (95% CI 0.58-1.15), MACCE HR 0.90 (95% CI 0.75-1.09)
Kip et al40 Outcomes Events/CR Total Events/IR Total
Repeat revascularization 328/59, 237/399
Death 55/595, 47/399
Continued
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Table 3. Continued
Study Results
Kloeter et al41 Outcomes Events/CR Total Events/IR Total
Repeat revascularization 10/101 23/149
MI 1/101 1/149
Death 0/101 3/149
Complete revascularization had considerably higher clinical restenosis (35% vs 22%, P=0.02)
Malkin et al22 Complete revascularization was significantly linked with survival (Adjusted OR 3.1, 95% CI 1.7-5.6)
Malkin et al23 Outcomes Events/CR Total Events/IR Total
Death 6/98 29/142 P<0.001
Mariani et al71 Outcomes Events/CR Total Events/IR Total
Repeat revascularization 1/49 7/159
MI 4/49 5/159
Death 0/49 2/159
In-hospital MACE occurred in 10% and 7.5% of patients with CR and IR, respectively (P=NS). At 12 months,
the reported MACE was 11.3% and 11.5% of patients with CR and IR, respectively
Nikolsky et al42 Survival in CR was 94.5%, vs 83.0% for those with IR (P<0.001). MI-free survival was considerably greater
in patients with CR than in those with IR (92.9% vs 79.9%, respectively). IR was a prognosticator of mortality
(95% CI 1.54-7.69; P=0.003)
Norwa-Otto et al43 There was no difference in mortality, cardiovascular deaths, or MI between CR and IR cohorts. The IR had
a higher rate of repeat revascularization
Park et al17 Outcomes Events/CR Total Events/IR Total
MACCE 114/2173 297/2915
Death 28/2173 65/2915
Myocardial infarction 4/2173 19/2915
Unplanned revascularization 86/2173 225/2915
Definite/probable stent thrombosis 11/2173 21/2915
Rosner et al8 (IR vs CR) Unadjusted HR (95% CI) for IR vs CR: death 1.43 (0.90-2.27); repeat revascularization
1.58 (1.28-1.96); MI 1.50 (1.18-1.89); MACE 1.47 (1.24 -1.74)
Sarno et al44 MACCEs in the 87% of the CR cohort at 24 months and 75% at 60 months. Definite stent thrombosis
occurred in 2.6% of the IR cohort and 3.9% of the CR cohort (P=0.45); definite or probable stent thrombosis
occurred in 6.5% in the IR cohort vs 8.6% in the CR cohort (P=0.41)
Sohn et al20 (CR vs IR) MACCE 34.7% vs 45.1%; adjusted hazard ratio [HR] 0.65, 95% CI 0.44-0.95, P=0.03; all-cause
death adjusted HR 0.48, 95% CI 0.29-0.80, P<0.01
Song et al45 (CR vs IR) MACE HR 0.64, 95% CI 0.46-0.88, P=0.01; revascularization HR 0.61, 95% CI 0.42-0.90, P=0.01;
death HR 0.87, 95% CI 0.48-1.57, P=0.64; MI HR 0.62, 95% CI 0.23-1.67, P=0.35. The rate of periprocedural MI and stent
thrombosis was comparable in the 2 cohorts (4.7% in the CR group vs 3.6% in the IR group, P=0.42; 1.6% vs 1.3%, P=0.72,
respectively)
Srinivas et al46 (CR vs IR) mortality HR 1.10 (95% CI 0.58-2.10) and repeat revascularization HR 0.92 (96% CI 0.66-1.29)
Tamburino et al47 (CR vs IR) primary composite endpoint HR 0.43 (0.29-0.63, P<0.0001), cardiac death HR 0.37 (0.15-0.92, P=0.03),
combination of cardiac death or MI HR 0.34 (0.16-0.75, P=0.008), and repeat revascularization
HR 0.45 (0.29-0.69, P=0.0003)
Valenti et al48 The survival rates were 91.6% and 87.4% in the CR and IR cohorts, respectively (P=0.025). CR was inversely proportional to
mortality (HR 0.44, 95% CI 0.22-0.87, P=0.021)
Van den Brand et al31 Outcomes Events/CR Total Events/IR Total
Unplanned revascularization 34/406 61/170
Myocardial infarction 20/406 10/170
Death 7/406 6/170
Wu et al5 Death (HR 1.12, 95% CI 1.01-1.26, P=0.04). Eight-year survival was 78.5% and 80.8% for IR and CR (P=0.04).
Mortality IR vs CR (adjusted HR 1.16, 95% CI 1.06-1.26, P=0.001)
Wu et al24 Among 6511 propensity-matched individuals (IR compared to CR) (79.3% vs 81.4%, P=0.004), and death
(HR 1.16, 95% CI 1.06-1.27). Five-year survival rate (IR 79.3% vs CR 81.4%, P=0.004)
Continued
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There are several reasons why IR might not be achieved in
PCI including patient clinical characteristics, lesion charac-
teristics, failed PCI, and operator choice. Independent
predictors of IR include advanced age, race, impaired LV
function, previous MI, and comorbidities such as peripheral
arterial disease, heart failure, diabetes, and renal failure.38
The most common lesion/anatomical characteristics for not
achieving CR with PCI in SYNTAX were the presence of CTO
(OR 2.46, 95% CI 1.81-3.39; P<0.01), bifurcation disease (RR
1.44, 95% CI 1.09-1.89; P<0.01), and diffuse disease or small
vessels (<2 mm) (RR 1.53, 95% CI 1.12-2.10, P<0.008).72
Previous studies have shown that patients with IR have a
greater prevalence of adverse clinical characteristics, are
older, and have more complex lesions than patients with
CR.8,35,38,39,73 These adverse procedural characteristics might
contribute to the associations reported. Most of the studies
included in this analysis are derived from registry data; hence,
the decision not to undertake CR by the operator may reflect
uncaptured comorbid conditions/general frailty of the patient
and so act as a surrogate of poor health status of the patients,
which will contribute to the poorer outcomes reported.
Although nearly all of the studies have adjusted for differ-
ences in baseline characteristics, the possibility of unmea-
sured confounding, particularly in studies derived from
registry data, is significant. Furthermore, the increased risk
associated with IR may relate to the complexity/extensive-
ness of coronary artery disease at baseline. For example, a
post hoc analysis of the ARTS trial revealed that IR was
associated with worse outcomes only in patients in the
highest SYNTAX score tertile, whereas in the low and middle
tertiles IR was not an independent predictor of adverse
outcomes.44
Our analysis does not allow comparison of outcomes of
patients undergoing IR in different settings such as elective
versus the ACS because the majority of studies do not report
outcomes by clinical presentation. The subgroup analysis of
ACS of 2 studies8,71 did not show any difference in mortality
or MACE between the 2 cohorts. The studies were hetero-
geneous, and 1 of them71 was not large enough to detect the
difference among the cohorts. Nevertheless, it has been
demonstrated that complete revascularization in STEMI
confers survival benefit.10-12 More recently, for example, the
DANAMI-3-PRIMULTI trial reported a 44% reduction in the
primary endpoint of all-cause mortality, nonfatal myocardial
infarction, and repeat revascularization (HR 0.56, 95% CI 0.38-
0.83; P=0.004). Following these trials, multiple meta-
analyses56,63,65,74-76 have suggested a significant survival
advantage in complete revascularization in patients with
STEMI. Similarly, in the post hoc analysis of the ACUITY Trial,8
which included 2954 ACS patients, IR is associated with an
increased risk of MACE. Unstable angina accounted for
approximately one third of the patients in the SYNTAX6 and
FAME trials.18,77,78 In the post hoc analysis18 of the FAME
trial, CR was compared to IR in patients who underwent FFR-
guided PCI. There was no significant difference in survival
between stable and unstable individuals at 24 months,
indicating a consistent treatment effect with the FFR inter-
vention. Further, a post hoc analysis of the SYNTAX trial6
performed subgroup analysis based on SYNTAX Revascular-
ization Index <70% versus >70%. The OR for patients with
unstable angina was 3.25 (95% CI 3.37-11.25), clearly
indicating a survival advantage for patients with CR.
Our meta-regression analysis suggests that outcomes
relate to the degree of CR, in agreement with several previous
studies. Indeed, post hoc analysis of the SYNTAX trial
suggests higher degrees of IR, as measured by the SYNTAX
revascularization index, were associated with increased
5-year cardiac death, AMI, and major adverse cardiac or
cerebrovascular events (MACCE).6 Similarly, Park et al17
showed in the EXCELLENT registry that patient-orientated
Table 3. Continued
Study Results
Yang et al49 No differences in outcomes between the 2 cohorts at follow-up.
Outcomes Events/CR Total Events/IR Total
Repeat revascularization 4/99 17/255
MI 1/99 4/255
Death 3/99 7/255
George et al50 (CR vs IR) Mortality (adjusted HR 0.70, 95% CI 0.56-0.87, P=0.002)
Hannan et al51 2.5-year Mortality CR vs CR for CTO, incomplete for ≥1 other lesions adjusted HR 1.11 (0.74, 1.68). 2.5-year
mortality CR vs IR for CTO adjusted HR 1.63 (1.28, 2.08), P<0.0001
Danzi et al52 Two-year cardiac death-free survival was better in the CR cohort compared to IR (96 vs 78 P=0.002)
Chang et al53 IR with drug-eluting stents in multivessel disease was associated with increased MI risk (HR 1.86, 95% CI 1.08-3.19, P=0.024)
and similar risk of death (HR 1.03, 95% CI 0.80-1.32; P=0.83) compared to CR
CABG indicates coronary artery bypass grafting; CR, complete revascularization; CTO, chronic total occlusion; IR, incomplete revascularization; MACE, major adverse cardiac events; MI,
myocardial infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; RSS, residual SYNTAX score; SRI, SYNTAX revascularisation index.
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composite endpoint rates (POCE) increased with increasing
residual syntax score tertiles. Finally, CTO revascularization
has been a matter of debate in recent years.50,79-81 Contem-
porary evidence from a large UK registry of 13 443 individuals
with CTO50 suggests that complete revascularization had a
survival advantage over partial revascularization with a hazard
ratio of 0.70 (95% CI 0.56-0.87). Our study confirms survival
benefit regarding complete revascularization of CTO with an
OR of 0.69 (95% CI 0.61-0.78). Similarly, a meta-analysis
of 7288 patients81 suggested that successful CTO recanal-
ization had a survival advantage and reduced surgical
revascularization.
Figure 2. Risk of death with complete vs incomplete revascularization. The odds of death (OR:0.69, 95% CI: 0.61–0.78) was significantly lower
in the patients who underwent complete revascularization. CR indicates complete revascularization; IR, incomplete revascularization.
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Limitations
There are several limitations associated with our analysis.
First, although we report an association between IR and
adverse clinical outcomes, we cannot infer a causal relation-
ship. We have shown an association between IR and adverse
outcomes, but it cannot be assumed that treating such
patients with IR with additional PCI to attain CR would
improve their prognosis. Second, for anatomical based
definitions of IR, there are no universally accepted definitions
of lesion “significance” with studies defining significant
lesions as those with diameter stenosis (DS) varying between
≥50% and ≥70% in vessels of diameter ≥1.5 mm in some
studies to ≥2.5 mm in other studies. Many of the studies
included in this analysis used visual assessment to define
lesion severity, which is known to have greater interobserver
variability and to overestimate percentage DS compared with
quantitative coronary angiograph (QCA).82 Interestingly, a
post hoc analysis of the ACUITY trial using QCA illustrated
that even when DS≥30% was used to define a significant
lesion, IR was independently associated with an increased risk
of MACE (HR 1.36, 95% CI 1.11-1.68), although the risk
increased with increasing DS thresholds (for DS threshold of
≥70%, HR 1.59, 95% CI 1.30-1.93). Score-based definitions of
IR, such as the residual SYNTAX score, overcome some of the
limitations around differences in anatomical definitions of
lesion significance used across studies, allowing comparisons
to be made more easily. In the current analysis we report a
similar prognostic impact of IR irrespective of whether this is
defined by anatomical or score-based definitions.
Figure 3. Risk of repeat revascularization with complete vs incomplete revascularization. The odds of repeat revascularization (OR: 0.60, 95%
CI: 0.45–0.80) was significantly lower in the patients who underwent complete revascularization. CR indicates complete revascularization; IR,
incomplete revascularization.
DOI: 10.1161/JAHA.116.004598 Journal of the American Heart Association 16
Incomplete Revascularization in Multivessel CAD Nagaraja et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 23, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Third, contemporary studies have shown that the
functional significance of lesions on the basis of fractional
flow reserve is a more important determinant of future
cardiac events than anatomical/angiographic appear-
ances.18,83-85 Operators may choose not to revascularize
lesions due to their functional nonsignificance or location
within vessels supplying infarcted and nonviable myocar-
dium. A recent post hoc analysis of the FAME study18
demonstrated that IR (as defined by residual SYNTAX score
and SYNTAX revascularization index) was not associated
with adverse outcome in the setting of complete functional
revascularization, supporting the hypothesis that functional
CR is more important than anatomical CR. The remaining
studies that report outcomes following IR included in this
analysis (with the exception of the aforementioned study18)
do not differentiate between the anatomical and the
functional significance of incompletely revascularized
lesions. The differences in the prognostic impact of
incomplete revascularization across the different studies
analyzed in this meta-analysis may relate to the above
limitations, mainly variability in the definition of what is
considered to be a significant coronary lesion, the site of
the lesion, whether the lesions that were not revascularized
were in infarcted nonviable territories or were functionally
significant, the sample size of the cohort studied, and
whether this would be adequately powered to detect a
statistically significant difference and the nature of the
cohort studied. Finally, most of the studies included in this
analysis are derived from registry data; hence, the decision
not to undertake CR by the operator may reflect
Figure 4. Risk of myocardial infarction with complete vs incomplete revascularization. The odds of myocardial infarction (OR: 0.64, 95% CI:
0.50–0.81) was significantly lower in the patients who underwent complete revascularization. CR indicates complete revascularization; IR,
incomplete revascularization.
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Figure 5. Risk of MACE with complete vs incomplete revascularization. The odds of MACE (OR:0.66, 95% CI: 0.51–0.85) were
significantly lower in the patients who underwent complete revascularization. CR indicates complete revascularization; IR,
incomplete revascularization, MACE, major adverse cardiac events.
Figure 6. Risk of stent thrombosis with complete vs incomplete revascularization. There was no difference in the rate of
stent thrombosis among the two cohorts. CR indicates complete revascularization; IR, incomplete revascularization.
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uncaptured comorbidity or general frailty of the patient and
so act as a surrogate of poor health status of the patients
that will contribute to the poorer outcomes reported.
Although nearly all of the studies have adjusted for
differences in baseline characteristics, there remains a
possibility of unmeasured confounding.
In conclusion, our analysis of data derived from over
150 000 patients undergoing PCI suggests that fewer than
half of all patients with multivessel coronary artery disease
have CR following PCI. We observe that CR is associated with
decreased incidence of mortality, myocardial infarction, and
MACE, irrespective of whether an anatomical or a score-based
definition of IR was used and that the magnitude of risk
relates to degree of CR. The findings of our analysis have
several practical implications for interventional cardiologists.
Our reported associations between IR and adverse clinical
outcomes suggest that in patients with MVD, consideration
should be given to the degree of CR that can be achieved by
PCI when discussing choice of revascularization modality
within the heart team, in addition to consideration of lesion
complexity, functional significance, patient characteristics,
and syntax score in line with current international recom-
mendations.86 At the very least these data speak of the need
for further carefully conducted randomized trials to address
this question.
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